Showing results (71-80 of 77) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Journal of Innate Immunity|March 18, 2016
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic FibrosisLaurent Meijer, Deborah J Nelson, Vladimir Riazanski, et al.Haematologica|January 5, 2019
Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trialFrancis Couturaud, Gilles Pernod, Emilie Presles, et al.Journal of Thrombosis and Haemostasis : JTH|January 30, 2026
Epidemiology of Venous Thromboembolism during Pregnancy and Postpartum: Results from the French Prospective Multicentre HEMOTHEPP studyEloïse Laouenan, François Anouilh, Emmanuelle Courtois-Communier, et al.The European Respiratory Journal|January 6, 2018
Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trialCécile Tromeur, Olivier Sanchez, Emilie Presles, et al.Lancet (London, England)|August 16, 2025
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysisPatrick Rossignol, Faiez Zannad, Ziad Massy, et al.NEJM Evidence|February 6, 2024
Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical PatientsDominique Mottier, Philippe Girard, Francis Couturaud, et al.Lancet (London, England)|March 1, 2025
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trialFrancis Couturaud, Jeannot Schmidt, Olivier Sanchez, et al.Pageof 8